Posts tagged Front Range
Boulder Channel 1 Presets at New Tech Meetup
Feb 10th
The Boulder Channel 1 crew present at Boulder New Tech Meetup. We talk about what we do, and what we would like to do as well as take questions from the 500 person crowd about how we manage our websites and who might be interested in looking at us for personal use or as a marketing tool for their business.
CU Women Put Away Pioneers, Eye No. 8 Cardinals
Dec 12th
DENVER – The unbeaten University of Colorado women’s basketball team shook off a lethargic start, took control with an 8-0 run and never looked back in dispatching the University of Denver 83-63 here Tuesday night.
Now the Buffaloes (8-0) can look ahead. Finally, they can focus on their biggest non-conference game – a Friday night date with No. 8 Louisville at the Coors Events Center. The Cardinals are 9-1, with their lone loss by one point (48-47) to archrival Kentucky.
In winning for only the second time in Denver against the Pioneers, the Buffs got a season-high 19 points from Brittany Wilson and 14 points and 11 rebounds from Chucky Jeffery. Leading scorer Arielle Roberson, who entered the game with a 17.3-point average, added 11.
DU defeated CU 70-69 in their most recent Magness Arena matchup on Nov. 16, 2010. The Buffs lead the series 6-2 and won for the third time this season against a Front Range opponent. Before making the trip down I-25 South, CU had beaten Wyoming (68-59) and Colorado State (72-46) in Boulder.
Tuesday’s first half produced 11 lead changes, but they all occurred in the first 10 minutes. DU (4-5) took advantage of CU’s sluggish start to go ahead by as many as five points (13-8) before the visitors roused themselves.
Finally focused, the Buffs made an 18-17 deficit their last of the game. They went on an 8-0 run, getting baskets from Jamee Swan, Roberson (her first of the game), Jeffery and Brittany Wilson on a fast-break assist from Jeffery to go up 25-18 with 6:22 before intermission.
From there until the halftime buzzer, CU increased its lead to 10 on two occasions and led 37-27 at the break. The Buffs got 12 first-half points from Brittany Wilson and nine from Jeffery. Morgan Van Riper-Rose kept the Pioneers close with 13, while none of her teammates managed more than four first-half points. She finished with a career-high 28.
CU shot 41.7 percent (15-for-36) from the field in the opening half to DU’s 37.5 percent (9-for-24). The Buffs owned the boards (25-13) and forced 10 Pioneer turnovers that resulted in seven CU points.
CU outscored DU 9-1 to open the second half and surge ahead 46-28. The Buffs didn’t allow the Pioneers their first field goal of the last 20 minutes until the 14:07 mark. A minute later, CU went up by 23 and wouldn’t allow DU within 15 points the rest of the night.
With 7:55 remaining, Roberson was assessed CU’s first technical foul of the season. The reason: Roberson apparently touched the ball before a Pioneer player was about to throw it in bounds after a made Buffs basket. CU was up 67-44 at the time and led by as many as 26 points in the final 4 minutes.
[includeme src=”http://c1n.tv/boulder/media/bouldersponsors.html” frameborder=”0″ width=”670″ height=”300″]
CU : Some good news for doggie lovers
Dec 11th
clinical study to treat canine pain
A University of Colorado Boulder professor and her biomedical spinoff company Xalud Therapeutics Inc. of San Francisco are teaming up with a Front Range veterinarian to conduct a clinical study targeting an effective treatment for dogs suffering from chronic pain.
Distinguished Professor Linda Watkins of CU-Boulder’s psychology and neuroscience department said the study involves treating ailing dogs with a gene therapy using Interleukin-10, or IL-10, a protein and anti-inflammatory that both dogs and humans produce naturally. Watkins is working with veterinarian Robert Landry of Mountain Ridge Animal Hospital and Pain Management Center in Lafayette, who will be treating canine patients suffering from chronic and painful conditions, some of which already are being treated with various other medications with limited success.
Animals perceive and experience several levels of pain that are similar to humans, and chronic pain can be debilitating and also shorten the lives of pets, said Landry, one of only a handful of credentialed American Academy of Pain Management practitioners in Colorado. Landry currently is seeking Denver-Boulder area pet owners who have dogs suffering from chronic pain and who might be interested in participating in the study, which is free.
The new study is driven by research spearheaded by Watkins indicating a type of cell known as glial cells found in the nervous system of mammals plays a key role in pain. Under normal conditions, glial cells act as central nervous system “housekeepers,” cleaning up cellular debris and providing support for neurons, said Watkins. But glial cells also can play a pivotal role in pain enhancement by exciting neurons that both transmit pain signals and release a host of chemical compounds that cause problems like chronic neuropathic pain and other medical issues.
The team will use Xalud’s lead product candidate, XT-101, a gene therapy that harnesses the power of the potent anti-inflammatory IL-10 to normalize glial activity and eliminate neuropathic pain for up to 90 days with a single injection.
The gene therapy based on IL-10 has a number of advantages, including suppressing glial activity in the spinal cord, stimulating tissue regeneration and growth, decreasing the production of pro-inflammatory substances and increasing the production of anti-inflammatory substances, Watkins said. Landry and Watkins also have been working with the American Kennel Club on potential funding for additional clinical studies involving the treatment of chronic pain in dogs, said Watkins.
“We have already tested this new therapy in two pet dogs, and both have had remarkable reversals of their pain for long durations after a single injection of the therapeutic,” she said. “Our early peek at the potential of this therapeutic treatment in dogs shows essentially the same positive effects we have seen in laboratory rats used in our studies that have been treated with the therapy.”
Watkins said demonstrating the efficacy and safety of the new gene therapy in a second species of mammal is important in terms of moving it forward to eventually meet FDA regulations for human clinical trials.
In addition to studying what triggers glial cells to become activated and begin releasing pain-enhancing substances and ways to control chronic pain, Watkins and her research team recently discovered that clinically prescribed opioids also activate glial cells and cause them to release pain-enhancing substances. “Our ultimate goal is to find a means by which clinical pain control can be improved so as to relieve human suffering,” she said.
To contact Landry about possible participation in the study by family dogs suffering chronic pain and that might benefit from the experimental treatment, call the Mountain Ridge Animal Hospital at 303-665-4852.
For more information on CU-Boulder’s psychology and neuroscience department visit http://psych-www.colorado.edu/. For more information on Xalud Therapeutics Inc. visit http://www.xaludthera.com/. For more information on Mountain Ridge Animal Hospital visit http://www.mountainridgevet.com/.
[includeme src=”http://c1n.tv/boulder/media/bouldersponsors.html” frameborder=”0″ width=”670″ height=”300″]
–